315 related articles for article (PubMed ID: 26631840)
1. Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.
Baldo A; Galanis E; Tangy F; Herman P
Hum Vaccin Immunother; 2016 May; 12(5):1102-16. PubMed ID: 26631840
[TBL] [Abstract][Full Text] [Related]
2. Measles virus.
Naim HY
Hum Vaccin Immunother; 2015; 11(1):21-6. PubMed ID: 25483511
[TBL] [Abstract][Full Text] [Related]
3. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector.
Tangy F; Naim HY
Viral Immunol; 2005; 18(2):317-26. PubMed ID: 16035943
[TBL] [Abstract][Full Text] [Related]
4. Attenuated measles virus as a vaccine vector.
Zuniga A; Wang Z; Liniger M; Hangartner L; Caballero M; Pavlovic J; Wild P; Viret JF; Glueck R; Billeter MA; Naim HY
Vaccine; 2007 Apr; 25(16):2974-83. PubMed ID: 17303293
[TBL] [Abstract][Full Text] [Related]
5. A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model.
Nürnberger C; Bodmer BS; Fiedler AH; Gabriel G; Mühlebach MD
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429338
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic measles viruses for cancer therapy.
Nakamura T; Russell SJ
Expert Opin Biol Ther; 2004 Oct; 4(10):1685-92. PubMed ID: 15461580
[TBL] [Abstract][Full Text] [Related]
7. Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression.
Julik E; Reyes-Del Valle J
J Virol; 2016 Jun; 90(11):5270-5279. PubMed ID: 26984727
[TBL] [Abstract][Full Text] [Related]
8. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
9. Measles virus as an oncolytic vector platform.
Blechacz B; Russell SJ
Curr Gene Ther; 2008 Jun; 8(3):162-75. PubMed ID: 18537591
[TBL] [Abstract][Full Text] [Related]
10. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice.
Combredet C; Labrousse V; Mollet L; Lorin C; Delebecque F; Hurtrel B; McClure H; Feinberg MB; Brahic M; Tangy F
J Virol; 2003 Nov; 77(21):11546-54. PubMed ID: 14557640
[TBL] [Abstract][Full Text] [Related]
11. Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.
Patel MR; Jacobson BA; Belgum H; Raza A; Sadiq A; Drees J; Wang H; Jay-Dixon J; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
J Thorac Oncol; 2014 Aug; 9(8):1101-10. PubMed ID: 25157763
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic measles virus strains as novel anticancer agents.
Msaouel P; Opyrchal M; Domingo Musibay E; Galanis E
Expert Opin Biol Ther; 2013 Apr; 13(4):483-502. PubMed ID: 23289598
[TBL] [Abstract][Full Text] [Related]
13. Attenuated oncolytic measles virus strains as cancer therapeutics.
Msaouel P; Iankov ID; Dispenzieri A; Galanis E
Curr Pharm Biotechnol; 2012 Jul; 13(9):1732-41. PubMed ID: 21740361
[TBL] [Abstract][Full Text] [Related]
14. Wild-type measles virus with the hemagglutinin protein of the edmonston vaccine strain retains wild-type tropism in macaques.
Takeuchi K; Nagata N; Kato SI; Ami Y; Suzaki Y; Suzuki T; Sato Y; Tsunetsugu-Yokota Y; Mori K; Van Nguyen N; Kimura H; Nagata K
J Virol; 2012 Mar; 86(6):3027-37. PubMed ID: 22238320
[TBL] [Abstract][Full Text] [Related]
15. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
16. hCD46 receptor is not required for measles vaccine Schwarz strain replication in vivo: Type-I IFN is the species barrier in mice.
Mura M; Ruffié C; Billon-Denis E; Combredet C; Tournier JN; Tangy F
Virology; 2018 Nov; 524():151-159. PubMed ID: 30199752
[TBL] [Abstract][Full Text] [Related]
17. Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates.
Rennick LJ; de Vries RD; Carsillo TJ; Lemon K; van Amerongen G; Ludlow M; Nguyen DT; Yüksel S; Verburgh RJ; Haddock P; McQuaid S; Duprex WP; de Swart RL
J Virol; 2015 Feb; 89(4):2192-200. PubMed ID: 25473055
[TBL] [Abstract][Full Text] [Related]
18. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.
Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW
BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685
[TBL] [Abstract][Full Text] [Related]
19. Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.
Msaouel P; Opyrchal M; Dispenzieri A; Peng KW; Federspiel MJ; Russell SJ; Galanis E
Curr Cancer Drug Targets; 2018; 18(2):177-187. PubMed ID: 28228086
[TBL] [Abstract][Full Text] [Related]
20. Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice.
Lal S; Peng KW; Steele MB; Jenks N; Ma H; Kohanbash G; Phillips JJ; Raffel C
Hum Gene Ther Clin Dev; 2016 Dec; 27(4):145-151. PubMed ID: 27604429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
